Long-term survival of favorable-risk patients with metastatic renal cell carcinoma treated with second-line axitinib in a multicenter phase II study.

被引：0
|
作者：
Tsimafeyeu, Ilya [1 ]
Borisov, Pavel S. [2 ]
Semenov, Andrey [3 ]
Leonenkov, Roman [4 ]
Novikova, Olga [5 ]
Gamayunov, Sergey [6 ]
Mikhailova, Nadezhda [7 ]
Bondarenko, Anastasia [8 ]
Abdelgafur, Ahmed [6 ]
机构：
[1] Kidney Canc Res Bur, Moscow, Russia
[2] City Clin Oncol Ctr, St Petersburg, Russia
[3] Ivanovo Canc Ctr, Ivanovo, Russia
[4] St Petersburg City Canc Ctr, St Petersburg, Russia
[5] Khabarovsk Reg Canc Ctr, Khabarovsk, Russia
[6] Republican Clin Oncol Ctr, Cheboksary, Russia
[7] Republican Clin Oncol Ctr, Kazan, Russia
[8] IM Sechenov First Moscow State Med Univ, Moscow, Russia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.332
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
332
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial.
    Rini, B. I.
    Escudier, B.
    Tomczak, P.
    Kaprin, A.
    Hutson, T. E.
    Szczylik, C.
    Tarazi, J. C.
    Rosbrook, B.
    Kim, S.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [42] RECORD-4: a multicenter phase 2 trial of second-line everolimus (EVE) in patients with metastatic renal cell carcinoma (mRCC)
    Cosgriff, Thomas
    Alyasova, Anna
    Ye, Dingwei
    Xie, Liping
    Kurteva, Galina
    Kowalyszyn, Ruben
    Neron, Yeni
    Collins, Latonya
    Brechenmacher, Thomas
    Lin, Chinjune
    Morgan, Liza
    Yang, Lin
    Motzer, Robert
    BJU INTERNATIONAL, 2015, 116 : 6 - 7
  • [43] Interferon treatment for Japanese patients with favorable-risk metastatic renal cell carcinoma in the era of targeted therapy
    Sazuka, Tomokazu
    Nihei, Naoki
    Nakamura, Kazuyoshi
    Sakamoto, Shinichi
    Fukasawa, Satoshi
    Komaru, Atsushi
    Ueda, Takeshi
    Igarashi, Tatsuo
    Ichikawa, Tomohiko
    KOREAN JOURNAL OF UROLOGY, 2015, 56 (03) : 205 - 211
  • [44] Overall survival (OS) and efficacy results of second-line treatment in patients (pts) with metastatic clear cell renal cell carcinoma (mRCC) treated in the randomized phase II BIONIKK trial.
    Vano, Yann-Alexandre
    Phan, Letuan
    Simonaggio, Audrey
    Bennamoun, Mostefa
    Pannier, Diane
    Chevreau, Christine
    Borchiellini, Delphine
    Maillet, Denis
    Gross-Goupil, Marine
    Laguerre, Brigitte
    Tournigand, Christophe
    Barthelemy, Philippe
    Coquan, Elodie
    Gravis, Gwenaelle
    Sun, Cheng-Ming
    Meylan, Maxime
    Fridman, Wolf-Herve
    Sautes-Fridman, Catherine
    Elaidi, Reza
    Oudard, Stephane
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [45] Validation of the IMDC Prognostic Model in Patients With Metastatic Renal-Cell Carcinoma Treated With First-Line Axitinib: A Multicenter Retrospective Study
    Konishi, Sakae
    Hatakeyama, Shingo
    Numakura, Kazuyuki
    Narita, Shintaro
    Inoue, Takamitsu
    Saito, Mitsuru
    Tokui, Noriko
    Yamamoto, Hayato
    Yoneyama, Takahiro
    Hashimoto, Yasuhiro
    Yoshikawa, Kazuaki
    Narita, Satoshi
    Kawaguchi, Toshiaki
    Habuchi, Tomonori
    Ohyama, Chikara
    CLINICAL GENITOURINARY CANCER, 2019, 17 (05) : E1080 - E1089
  • [46] Long-term survival in metastatic melanoma patients treated with sequential biochemotherapy: Report of a phase II study
    Neri, B.
    Vannozzi, L.
    Fulignati, C.
    Pantaleo, P.
    Pantalone, D.
    Paoletti, C.
    Perfetto, F.
    Turrini, M.
    Mazzanti, R.
    CANCER INVESTIGATION, 2006, 24 (05) : 474 - 478
  • [47] Does the Time to Start First-Line Treatment Influence the Survival of Favorable-Risk Patients With Metastatic Renal Cell Carcinoma? Results of the MetaSurv-UroCCR 79 Study
    Rolley, Cyrielle
    Barthelemy, Philippe
    Bensalah, Karim
    Nouhaud, Francois-Xavier
    Villers, Arnauld
    Bruyere, Franck
    Lebdai, Souhil
    Ricard, Solene
    Gross-Goupil, Marine
    Roupret, Morgan
    Bernhard, Jean-Christophe
    Bigot, Pierre
    CLINICAL GENITOURINARY CANCER, 2022, 21 (01) : 194 - 202
  • [48] Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma
    Rini, Brian I.
    Wilding, George
    Hudes, Gary
    Stadler, Walter M.
    Kim, Sinil
    Tarazi, Jamal
    Rosbrook, Brad
    Trask, Peter C.
    Wood, Laura
    Dutcher, Janice P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (27) : 4462 - 4468
  • [49] Predictors of Survival in Favorable Risk Patients with Metastatic Renal Cell Carcinoma Treated with a Single-Agent First-Line Therapy
    Mizuno, Ryuichi
    Takamatsu, Kimiharu
    Yasumizu, Yota
    Tanaka, Nobuyuki
    Takeda, Toshikazu
    Morita, Shinya
    Matsumoto, Kazuhiro
    Kosaka, Takeo
    Asanuma, Hiroshi
    Mikami, Shuji
    Oya, Mototsugu
    UROLOGIA INTERNATIONALIS, 2022, 106 (11) : 1145 - 1149
  • [50] Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinoma
    Dodd, PM
    McCaffrey, JA
    Mazumdar, M
    Icasiano, E
    Higgins, G
    Herr, H
    Bajorin, DF
    INVESTIGATIONAL NEW DRUGS, 2000, 18 (03) : 247 - 251
12345